CIK 0001649989
- Non-accelerated filer
- Smaller reporting company
Outlook Therapeutics, Inc.
Sign in to watch- Ticker
- OTLK
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Sep 30
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 383982704
- Phone
- +1 609-619-3990
- Business address
- 111 S. WOOD AVENUE, UNIT #100, ISELIN, NJ, 08830
- Former names
- Oncobiologics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 71 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-07-17 | KENYON LAWRENCE A CEO, Pres, CFO, Treas & Secy | Grant or award · Stock Option (Right to Buy) | +450,000 | 450,000 | ||
| 2020-07-17 | Huang Andong Director | Grant or award · Stock Option (Right to Buy) | +125,000 | 125,000 | ||
| 2020-07-17 | HILZINGER KURT J Director | Grant or award · Stock Option (Right to Buy) | +210,000 | 210,000 | ||
| 2020-07-17 | Haddadin Yezan Munther Director | Grant or award · Stock Option (Right to Buy) | +135,000 | 135,000 | ||
| 2020-07-17 | Gangolli Julian S Director | Grant or award · Stock Option (Right to Buy) | +125,000 | 125,000 | ||
| 2020-07-17 | Auffarth Gerd Director | Grant or award · Stock Option (Right to Buy) | +125,000 | 125,000 | ||
| 2020-07-15 | Syntone Ventures LLC 10% owner | Purchase | +823,045 | $1.22 | $1000K | 16,823,045 |
| 2020-07-01 | Gangolli Julian S Director | Grant or award · Stock Option (Right to Buy) | +35,006 | $0.99 | $34K | 35,006 |
| 2020-07-01 | Huang Andong Director | Grant or award · Stock Option (Right to Buy) | +11,376 | $0.99 | $11K | 11,376 |
| 2020-07-01 | Auffarth Gerd Director | Grant or award · Stock Option (Right to Buy) | +19,874 | $0.99 | $20K | 19,874 |
| 2020-06-19 | Huang Andong Director | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2020-04-20 | Gangolli Julian S Director | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2020-04-20 | Auffarth Gerd Director | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2020-03-23 | BioLexis Pte Ltd. Director | Option exercise | +29,358,621 | 50,965,058 | ||
| 2020-03-23 | BioLexis Pte Ltd. Director | Option exercise · Series A-1 Convertible Preferred Stock | −68,112 | 0 | ||
| 2020-03-19 | Evanson Jeff Chief Commercial Officer | Grant or award | +1,207,457 | 1,207,457 | ||
| 2020-03-19 | Dagnon Terry Chief Operating Officer | Grant or award | +1,207,457 | 1,207,457 | ||
| 2020-03-19 | BioLexis Pte Ltd. Director | Returned to the company · Series A-1 Convertible Preferred Stock | −68,112 | 0 | ||
| 2020-03-19 | BioLexis Pte Ltd. Director | Grant or award · Series A-1 Convertible Preferred Stock | +68,112 | 68,112 | ||
| 2020-03-19 | KENYON LAWRENCE A CEO, Pres, CFO, Treas & Secy | Grant or award · Stock Option (Right to Buy) | +216,435 | 216,435 |
Page 11 of 14 · 276 trades